A Clinical Pharmacodynamic and Pharmacogenetic Study of OPB-51602 in Patients With Advanced Solid Tumours View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2011-2015

ABSTRACT

OPB-51602 is a novel oral small molecule STAT3 inhibitor developed by Otsuka Pharmaceutical Company, Ltd, and is currently undergoing clinical investigation at the National University Health System (NUHS), Singapore. The proposed correlative pharmacodynamic and pharmacogenetic biomarker study is initiated and funded by the investigators, and will be conducted in conjunction with the extension phase I protocol of OPB-51602 in patients with advanced solid tumours (Study code 266-09-801-01/ DSRB protocol B/09/514). All biomarker and pharmacogenetic samples will be collected, stored and analysed at the local laboratory of the study site (Cancer Science Institute, National University Health System, Singapore, Dr Boon-Cher Goh). More... »

URL

https://clinicaltrials.gov/show/NCT01867073

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "OPB-51602 is a novel oral small molecule STAT3 inhibitor developed by Otsuka Pharmaceutical Company, Ltd, and is currently undergoing clinical investigation at the National University Health System (NUHS), Singapore. The proposed correlative pharmacodynamic and pharmacogenetic biomarker study is initiated and funded by the investigators, and will be conducted in conjunction with the extension phase I protocol of OPB-51602 in patients with advanced solid tumours (Study code 266-09-801-01/ DSRB protocol B/09/514). All biomarker and pharmacogenetic samples will be collected, stored and analysed at the local laboratory of the study site (Cancer Science Institute, National University Health System, Singapore, Dr Boon-Cher Goh).", 
    "endDate": "2015-05-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT01867073", 
    "keywords": [
      "pharmacogenetic study", 
      "patient", 
      "small molecule", 
      "pharmaceutical company", 
      "LTD", 
      "clinical investigation", 
      "health system", 
      "Singapore", 
      "biomarker study", 
      "extension", 
      "advanced solid tumor", 
      "protocol", 
      "biomarker", 
      "pharmacogenetics", 
      "laboratory", 
      "study site", 
      "Sciences Institute"
    ], 
    "name": "A Clinical Pharmacodynamic and Pharmacogenetic Study of OPB-51602 in Patients With Advanced Solid Tumours", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT01867073"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00014.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.412106.0", 
        "type": "Organization"
      }
    ], 
    "startDate": "2011-05-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1038/nrc1275", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031068002", 
          "https://doi.org/10.1038/nrc1275"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075031459", 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT01867073"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT01867073'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT01867073'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT01867073'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT01867073'


 

This table displays all metadata directly associated to this object as RDF triples.

42 TRIPLES      16 PREDICATES      34 URIs      26 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT01867073 schema:about anzsrc-for:3142
2 schema:description OPB-51602 is a novel oral small molecule STAT3 inhibitor developed by Otsuka Pharmaceutical Company, Ltd, and is currently undergoing clinical investigation at the National University Health System (NUHS), Singapore. The proposed correlative pharmacodynamic and pharmacogenetic biomarker study is initiated and funded by the investigators, and will be conducted in conjunction with the extension phase I protocol of OPB-51602 in patients with advanced solid tumours (Study code 266-09-801-01/ DSRB protocol B/09/514). All biomarker and pharmacogenetic samples will be collected, stored and analysed at the local laboratory of the study site (Cancer Science Institute, National University Health System, Singapore, Dr Boon-Cher Goh).
3 schema:endDate 2015-05-01T00:00:00Z
4 schema:keywords LTD
5 Sciences Institute
6 Singapore
7 advanced solid tumor
8 biomarker
9 biomarker study
10 clinical investigation
11 extension
12 health system
13 laboratory
14 patient
15 pharmaceutical company
16 pharmacogenetic study
17 pharmacogenetics
18 protocol
19 small molecule
20 study site
21 schema:name A Clinical Pharmacodynamic and Pharmacogenetic Study of OPB-51602 in Patients With Advanced Solid Tumours
22 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT01867073
23 schema:sdDatePublished 2019-03-07T15:25
24 schema:sdLicense https://scigraph.springernature.com/explorer/license/
25 schema:sdPublisher N00b3207ebe5645acaa11061139dd20fd
26 schema:sponsor https://www.grid.ac/institutes/grid.412106.0
27 schema:startDate 2011-05-01T00:00:00Z
28 schema:subjectOf sg:pub.10.1038/nrc1275
29 https://app.dimensions.ai/details/publication/pub.1075031459
30 schema:url https://clinicaltrials.gov/show/NCT01867073
31 sgo:license sg:explorer/license/
32 sgo:sdDataset clinical_trials
33 rdf:type schema:MedicalStudy
34 N00b3207ebe5645acaa11061139dd20fd schema:name Springer Nature - SN SciGraph project
35 rdf:type schema:Organization
36 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
37 rdf:type schema:DefinedTerm
38 sg:pub.10.1038/nrc1275 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031068002
39 https://doi.org/10.1038/nrc1275
40 rdf:type schema:CreativeWork
41 https://app.dimensions.ai/details/publication/pub.1075031459 schema:CreativeWork
42 https://www.grid.ac/institutes/grid.412106.0 schema:Organization
 




Preview window. Press ESC to close (or click here)


...